Format

Send to

Choose Destination
See comment in PubMed Commons below
Ann N Y Acad Sci. 2013 Jul;1290:12-20. doi: 10.1111/nyas.12205.

Resveratrol in the management of human cancer: how strong is the clinical evidence?

Author information

  • 1Cancer Chemoprevention Group, Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester, United Kingdom.

Abstract

Among the plethora of biochemical mechanisms engaged by resveratrol in preclinical systems, its anticarcinogenic effects represent some of the most convincing and intriguing. As outlined in this review, there is considerable interest in developing resveratrol for cancer prevention and treatment. The plasma pharmacokinetics of resveratrol in humans are now reasonably well defined, and studies have shown that repeated daily doses up to 1 g are safe and well tolerated, although gastrointestinal toxicity is observed at higher intakes. However, care is needed regarding underlying conditions in specific patient groups, and there is potential for drug interactions at doses greater than 1 gram. Little is known regarding the pharmacodynamic effects of resveratrol in humans, but the observation that it modulates components of the insulin-like growth factor system in the plasma of volunteers is encouraging. While the knowledge base that helps determine whether resveratrol may be useful in cancer management has increased substantially in recent years, important questions remain.

© 2013 New York Academy of Sciences.

KEYWORDS:

biomarkers; cancer; clinical trial; colon; pharmacokinetics; resveratrol

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Write to the Help Desk